Rein Therapeutics Inc.

RNTX | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.79

-$0.01 (-1.25%)

At close: Sep 21, 2026, 4:00 PM ET

$0.80

+$0.01 (+1.27%)

Pre-market: Sep 22, 2026, 4:06 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.25%

(1D)

Rating

Updated: Aug 13, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $22.21M

1D Range

0.79 0.80

52W Range

0.69 2.18

Valuation (TTM)

PE -0.46

PB 0.40

EV/EBITDA 0.88

Valuation (NTM)

Forward PE N/A

Forward PEG -0.40

Price Target $6

Cash Flow

FCF Yield -84.8%

SBC Adj. FCF Yield -93.9%

SBC Impact -10.8%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 30.0% | 24.9%

FCF 3Y | 5Y -9.6% | 7.0%

Returns

ROA -75.4%

ROE -234.4%

ROIC -36.4%

Financial Health

Net Cash

$40.65M

Current Ratio 4.27

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The c...

Sector Healthcare

Industry Biotechnology

Employees 10

IPO Date Jun 28, 2017

Website www.reintx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

Upside

+659.49%

Buy (1)

Hold (1)

Sell (0)

Analyst Details ➞